Related Experiment Video
Updated: Oct 20, 2025

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2
Rinath Jeselsohn1, Rachel Schiff2, Albert Grinshpun3
1Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Division of Molecular and Cellular Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA.
Resistance to CDK4/6 inhibitors is a challenge. A new study identifies cyclin E-CDK2 and Myc signaling as key resistance pathways and introduces a novel CDK2/4/6 inhibitor.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cyclin-dependent kinase (CDK) 4/6 inhibitors are crucial in cancer therapy.
- Acquired resistance limits the long-term efficacy of CDK4/6 inhibitors.
- Understanding resistance mechanisms is vital for developing next-generation therapies.
Purpose of the Study:
- To elucidate the molecular mechanisms driving resistance to CDK4/6 inhibitors.
- To identify novel therapeutic targets for overcoming treatment resistance.
- To develop a new inhibitor targeting key resistance pathways.
Main Methods:
- Utilized a CRISPR activation (CRISPRa) screen to identify genes conferring resistance.
- Analyzed the role of identified pathways in CDK4/6 inhibitor resistance.
- Developed and characterized a novel selective inhibitor of CDK2, CDK4, and CDK6.
Main Results:
- Identified the cyclin E-CDK2 axis as a critical mediator of resistance.
- Uncovered the involvement of Myc signaling in acquired resistance.
- Developed PF-06873600, a potent and selective inhibitor targeting CDK2/4/6.
Conclusions:
- The cyclin E-CDK2 axis and Myc signaling are key drivers of resistance to CDK4/6 inhibitors.
- Targeting CDK2 in combination with CDK4/6 inhibition may overcome resistance.
- PF-06873600 represents a promising therapeutic strategy for resistant cancers.
More Related Videos
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle